05:26 PM EST, 01/15/2025 (MT Newswires) -- Cellectis ( CLLS ) filed a registration statement with the US Securities and Exchange Commission on Wednesday for the potential resale of up to 44 million ordinary shares, including in the form of American Depository Shares, by AstraZeneca Holdings from time to time.

Cellectis ( CLLS ) said it will not receive any proceeds from the sale.